Home › Funding Recipients

We will upload information about the latest recipients to have been awarded HRC funding for all of our funding opportunities as this information becomes officially available.

The information provided is for ‘year to date’ funding.

Previous Recipient List

  • 2009 Funding Round
    Dr Jacqueline Cumming
    Victoria University of Wellington
    Improving health system performance: an economic analysis of primary care reform
    $522,913
    36 months
  • 2006 Funding Round
    Dr Jacqueline Cumming
    Victoria Link Limited
    Equity, variation and convergence in surgeons' clinical judgements of priority
    $1,093,031
    36 months
  • 2016 funding round - project
    Professor Jackie Cumming
    Victoria University of Wellington
    Exploring the development and impact of changes in community pharmacy services
    $1,185,380
    42 months
    Lay summary
  • Project
    Professor Jacqueline Cumming
    Victoria University of Wellington
    Integrated services to improve the health of Pacific peoples
    $1,194,152
    42 months
    Lay summary
  • 2016 Funding Round - Project
    Professor Christopher Cunningham
    Massey University, Wellington
    Me Mutu Kai Paipa - Improving the provision of cessation to New Zealand smokers
    $577,719
    24 months
    Lay summary
  • Project
    Dr Elana Curtis
    University of Auckland
    Examining emergency department inequities: do they exist?
    $899,943
    24 months
    Lay summary
  • 2008 Funding Round
    Professor Wayne Cutfield
    The University of Auckland
    Assessment of pituitary function following traumatic brain injury in infancy
    $616,770
    24 months
  • 2012 Funding Round
    Dr Stuart Dalziel
    Auckland District Health Board
    RCT of Levetiracetam vs. Phenytoin for Status Epilepticus in Children
    $1,198,986
    36 months
  • 2012 Funding Round
    Professor Brian Darlow
    University of Otago, Christchurch
    Cure Kids
    New Zealand Very Low Birthweight Young Adults: Mapping the Road Ahead
    $1,150,400
    36 months
  • 2013 Funding Round
    Associate Professor Alan Davidson
    The University of Auckland
    Understanding kidney injury and the role of HNF1beta
    $884,664
    36 months
  • 2013 Funding Round
    Associate Professor Alan Davidson
    The University of Auckland
    Understanding how WT1 and its binding partner WTX cause renal disease
    $1,171,726
    36 months
  • 2015 Funding Round - Project
    Associate Professor Alan Davidson
    The University of Auckland
    The role of the Pax-Notch pathway in kidney disease
    $1,067,513
    36 months
    Lay summary
  • Project
    Associate Professor Alan Davidson
    University of Auckland
    Kidney organoids: Modelling kidney injury and preclinical drug testing
    $1,182,356
    36 months
    Lay summary
  • 2008 Funding Round
    Professor Peter Davis
    The University of Auckland
    Improving health systems performance: enhancing hopsital outcomes
    $1,727,442
    48 months
  • 2014 Funding Round – Project
    Professor Peter Davis
    The University of Auckland
    Life-course predictors of mortality inequalities
    $1,091,258
    36 months
    Lay summary
  • 2010 Funding Round
    Associate Professor Catherine Day
    University of Otago, Dunedin
    Uncovering how inhibitor of apoptosis proteins regulate cell survival
    $991,988
    36 months
  • Project
    Professor Catherine Day
    University of Otago, Dunedin
    Integration of inflammatory signalling by TNF receptor associated factors
    $1,185,038
    36 months
    Lay summary
  • 2014 Funding Round – Project
    Dr Janak de Zoysa
    Waitemata District Health Board
    CKD-FIX: Trial of xanthine oxidase inhibition to slow kidney disease progression
    $990,685
    48 months
    Lay summary
  • Project
    Dr Justin Dean
    University of Auckland
    Targeting IGF-1 signalling for repair of preterm brain dysmaturation
    $1,157,670
    36 months
    Lay summary
  • 2007 Funding Round
    Professor William Denny
    The University of Auckland
    Dual activation of anticancer prodrugs by hypoxia and reductase-armed adenovirus
    $1,150,069
    36 months